NCT00215514: Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Completed | 1 | 25 | US | Epirubicin, Cisplatin, 5-Fluorouracil (5-FU), Radiation | Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital | Stomach Cancer, Gastric Cancer, Gastro-esophageal Junction Cancer | 11/03 | 07/14 | | |
EMD 72000-024, NCT00113581: Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer |
|
|
| Completed | 1 | 26 | Europe | EMD 72000 (matuzumab) + ECX | Merck KGaA, Darmstadt, Germany | Esophageal Cancer, Gastric Cancer | 05/06 | 01/07 | | |
VEOX, NCT01386346: Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer |
|
|
| Completed | 1 | 12 | US | Azacitidine, Vidaza®, 5-Azacitidine, Oxaliplatin, Eloxatin, Epirubicin, Ellence, Capecitabine, Xeolda | Weill Medical College of Cornell University, Celgene Corporation | Esophageal Cancer, Malignant Neoplasm of Cardio-esophageal Junction of Stomach | 08/14 | 09/18 | | |
